{
  "symbol": "SXTP",
  "company_name": "60 Degrees Pharmaceuticals Inc",
  "ir_website": "https://60degreespharma.com/investors-2/",
  "structured_data": [
    {
      "section_name": "News Releases",
      "links": [
        {
          "title": "Current News Releases",
          "url": "https://investors.60degreespharma.com/news-events/news-releases",
          "content": "[Skip to content](#lfg-main-content)\n\n![](/sites/g/files/knoqqb81531/themes/site/pid7950/dist/images/FPO/galaxy-overlay-2.png)\n\n# News Releases\n\nYear All20242023\n\n2024\n\n[60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results](/news-releases/news-release-details/60-degrees-pharmaceuticals-announces-third-quarter-2024-results)\n\nQ3 2024 sales revenue increased 164% year-over-year to $135 thousand . Sequential (quarter-over-quarter) net product revenue growth of 8.3%. Gross profit increased from ( $20 thousand ) to $24 thousand . WASHINGTON , Nov. 14, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. \n\nNovember 14, 2024 \n\n[PDF Version](/node/7336/pdf)\n\n[Read More](/news-releases/news-release-details/60-degrees-pharmaceuticals-announces-third-quarter-2024-results)\n\n[60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. Launch](/news-releases/news-release-details/60-degrees-pharmaceuticals-inc-announces-arakodar-promotional)\n\nHighlights include increased ARAKODA ® ( tafenoquine ) brand awareness and utilization through virtual sales outreach using digital behavioral analytics and a co-pay program to assist consumers with out-of-pocket costs. ARAKODA is the only new antimalarial in over a decade and is differentiated by \n\nOctober 3, 2024 \n\n[PDF Version](/node/7296/pdf)\n\n[Read More](/news-releases/news-release-details/60-degrees-pharmaceuticals-inc-announces-arakodar-promotional)\n\n[60 Degrees Pharmaceuticals, Inc. Announces Closing of $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules](/news-releases/news-release-details/60-degrees-pharmaceuticals-inc-announces-closing-4-million)\n\nWASHINGTON , Sept. 06, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced the closing of its previously announced private placement, priced \n\nSeptember 6, 2024 \n\n[PDF Version](/node/7261/pdf)\n\n[Read More](/news-releases/news-release-details/60-degrees-pharmaceuticals-inc-announces-closing-4-million)\n\n[60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules](/news-releases/news-release-details/60-degrees-pharmaceuticals-inc-announces-4-million-private)\n\nWASHINGTON , Sept. 04, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced that it has entered into definitive agreements for the issuance and \n\nSeptember 4, 2024 \n\n[PDF Version](/node/7251/pdf)\n\n[Read More](/news-releases/news-release-details/60-degrees-pharmaceuticals-inc-announces-4-million-private)\n\n[60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements](/news-releases/news-release-details/60-degrees-pharmaceuticals-inc-regains-compliance-nasdaq-listing)\n\nWASHINGTON , Aug. 28, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals , Inc. (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that on August 26, 2024 it received written notice from the Listing \n\nAugust 28, 2024 \n\n[PDF Version](/node/7241/pdf)\n\n[Read More](/news-releases/news-release-details/60-degrees-pharmaceuticals-inc-regains-compliance-nasdaq-listing)\n\n[60 Degrees Pharmaceuticals Announces Second Quarter 2024 Results](/news-releases/news-release-details/60-degrees-pharmaceuticals-announces-second-quarter-2024-results)\n\nQ2 2024 net product revenues doubled year-over-year to $125 thousand Sequential (quarter-over-quarter) net product revenue growth of 18.3% Gross profit increased from ( $124 thousand ) to $35 thousand , year-over-year WASHINGTON , Aug. 14, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. \n\nAugust 14, 2024 \n\n[PDF Version](/node/7221/pdf)\n\n[Read More](/news-releases/news-release-details/60-degrees-pharmaceuticals-announces-second-quarter-2024-results)\n\n[60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb Study](/news-releases/news-release-details/60-degrees-pharma-provides-university-kentucky-right-reference)\n\nUniversity of Kentucky will commence a Phase IIb clinical study of drug development candidate SJ733 for treatment of vivax malaria. SJ733 will be combined with a single dose of tafenoquine in the study. The right of reference allows FDA to review 60 Degrees Pharma’s regulatory file when the agency \n\nAugust 12, 2024 \n\n[PDF Version](/node/7206/pdf)\n\n[Read More](/news-releases/news-release-details/60-degrees-pharma-provides-university-kentucky-right-reference)\n\n[60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock Split](/news-releases/news-release-details/60-degrees-pharmaceuticals-inc-announces-112-reverse-stock-split)\n\nWASHINGTON , Aug. 06, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that it will effect a 1-for-12 reverse stock split (“Reverse Stock Split”) of \n\nAugust 6, 2024 \n\n[PDF Version](/node/7201/pdf)\n\n[Read More](/news-releases/news-release-details/60-degrees-pharmaceuticals-inc-announces-112-reverse-stock-split)\n\n[60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA® Supply Chain Upgrade Support](/news-releases/news-release-details/60-degrees-pharmaceuticals-awarded-contract-us-army-arakodar)\n\n60 Degrees Pharmaceuticals has been awarded a contract with the United States Army Medical Materiel Development Activity to facilitate commercial validation of new bottle and replacement blister packaging of ARAKODA ® ( tafenoquine ), the Company’s FDA-approved product indicated for malaria \n\nJuly 25, 2024 \n\n[PDF Version](/node/7181/pdf)\n\n[Read More](/news-releases/news-release-details/60-degrees-pharmaceuticals-awarded-contract-us-army-arakodar)\n\n[60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis Study](/news-releases/news-release-details/60-degrees-pharmaceuticals-signs-clinical-trial-agreements-all)\n\nThe Tafenoquine for Babesiosis clinical trial will be conducted at three sites: Yale University , Rhode Island Hospital and Tufts Medical Center Patient enrollment has begun; interim results anticipated by September, 2025 In the Northeast U.S. , the incidence of babesiosis has been increasing; \n\nJuly 19, 2024 \n\n[PDF Version](/node/7161/pdf)\n\n[Read More](/news-releases/news-release-details/60-degrees-pharmaceuticals-signs-clinical-trial-agreements-all)\n\nDisplaying 1 - 10 of 26 \n\nSearch Investors\n\nSearch this site\n\nSubmit\n"
        }
      ]
    }
  ]
}